Solid is excited to announce that new grants from Alex’s Wish and Duchenne Now will help drive progress on our gene therapy programs. The generous grants from both organizations will support our efforts to better understand how to quantify dystrophin and the impact of gene therapy on Duchenne muscular dystrophy (DMD). Our hope is that this work will accelerate timelines for necessary preclinical work and help us validate data quickly and efficiently.
The grants include:
- Duchenne Now: The U.K. members led organization founded by Tony Levene, Paul Fitzpatrick and Vici Richardson has committed a one-time grant of $150,000. This grant is the second that Duchenne Now has provided to Solid. The first, which we announced in June, is to fund our Disease Modifying Therapy programs.
- Alex’s Wish: The charity, also based in the U.K., has committed a one-time grant of £50,000. Founded by Emma and Andy Hallam to help find a treatment for their son Alex, this is the first time Alex’s Wish has partnered with Solid.
“Solid is proud to establish meaningful and impactful relationships with DMD charities to accelerate the progress of as many of our programs as possible,” said Kerry Rosenfeld, lead of Solid Patient Advocacy in Europe. “We believe this work will bring us closer to finding effective treatments for this devastating disease.”
If you are a charity and would like to partner with Solid on ongoing projects, please click here.